A
Fiscal year ends October Quarters are offset from the calendar — Q1 is Nov–Jan

Agilent Technologies, Inc. is a life sciences, diagnostics, and applied markets company providing application-focused solutions including instruments, software, services, and consumables for laboratory workflows. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Its Life Sciences and Diagnostics Markets segment offers liquid chromatography and mass spectrometry instruments, cell analysis platforms, pathology solutions for cancer diagnostics, genomics reagents for next-generation sequencing, and biomolecular analysis tools. This segment also includes a specialty contract development and manufacturing organization (CDMO) that produces active pharmaceutical ingredients for oligonucleotide-based therapeutics and antibody-drug conjugates, supported by the BIOVECTRA business. The Agilent CrossLab segment provides laboratory automation, software, informatics, and consumables across various end markets. The Applied Markets segment supplies gas chromatography, spectroscopy, and vacuum solutions for identifying and analyzing physical and biological properties of substances. Agilent serves pharmaceutical, biopharmaceutical, clinical, academic, government, and industrial customers globally, with primary research and manufacturing sites in the United States, Europe, and Asia.

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Medical Instruments & Supplies Homepage agilent.com
Sector Healthcare IR page investor.agilent.com/financials
Tags
liquid chromatography, mass spectrometry, flow cytometry, pathology diagnostics, genomics, contract development and manufacturing, oligonucleotide therapeutics, laboratory automation, gas chromatography, spectroscopy, biomolecular analysis, companion diagnostics, BIOVECTRA, Agilent TapeStationDx, ICP-MS 9500, OpenLab Sync, 1290 Infinity III Fluorescence Detector, Ultra Inert columns, Agilent Plasmid Topology kit, NovoStation Sample, ADS 2, CrossLab Connect
Press page —

Metrics

Valuation  
Market cap $ 48.586B
Market cap (USD) $ 48.586B
P/E 33.92
PEG 26.38
P/BV 6.60
P/S 6.59
P/OCF 30.20
P/FCF 38.35
Dividend yield 0.59%
Turnover / mcap —
Returns  
ROE 20.6%
ROI 12.9%
ROIC 13.3%
Profit margin 18.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 1.3%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 49.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 51
Quality score 10.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 6.948B 6.51B 6.833B 6.848B 6.319B 5.339B 5.163B 4.914B 4.472B 4.202B 4.038B 6.981B 6.782B 6.858B 6.615B 5.444B 4.481B 5.774B 5.42B 777M 5.139B 7.181B 6.056B 6.01B 765M 10.773B
Net profit 1.303B 1.289B 1.24B 1.254B 1.21B 719M 1.071B 316M 684M 462M 401M 504M 724M 1.153B 1.012B 684M -31M 693M 638M 3.307B 327M 349M -2.058B -1.032B 174M 757M
Free cash flow 1.152B 1.373B 1.474B 1.021B 1.297B 802M 866M 910M 713M 654M 393M 506M 957M 1.034B 1.072B 597M 280M 602M 815M 449M 760M 545M -349M -886M -995M 14M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 128.35 148.48 111.82 139.5 157.53 103.52 76.63 70.54 64.2 47.09 34.33 56.98 51.25 38.45 35 34.94 27.83 29.66 39.1 33.9 — — — — — —
Price performance 12m -0.14 0.33 -0.2 -0.11 0.52 0.35 0.09 0.1 0.36 0.37 -0.4 0.11 0.33 0.1 0 0.26 -0.06 -0.24 0.15 — — — — — — —

Filed figures

Figure Oct 2016 Oct 2017 Oct 2018 Oct 2019 Oct 2020 Oct 2021 Oct 2022 Oct 2023 Oct 2024 Oct 2025
Balance sheet detail
Trade receivables (USD) 631M 724M 776M 930M 1.04B 1.17B 1.41B 1.29B 1.32B 1.49B
↳ YoY growth +4.1% +14.7% +7.2% +19.8% +11.6% +12.9% +19.9% -8.1% +2.6% +12.3%
↳ 5y CAGR -6.0% -4.7% -2.9% -1.1% +11.4% +13.2% +14.2% +10.7% +7.3% +7.5%
Borrowings, current (USD) 0.00 210M 0.00 616M 75M 0.00 36M 0.00 45M 304M
Borrowings, non-current (USD) 1.91B 1.8B 1.8B 1.79B 2.28B 2.73B — — — —
Lease liabilities (USD) — — — — 178M 182M 152M 164M 184M 189M
Cash and deposits (USD) 2.29B 2.68B 2.25B 1.38B 1.44B 1.48B 1.05B 1.59B 1.33B 1.79B
Intangible assets (USD) 408M 361M 491M 1.11B 831M 981M 821M 475M 547M 445M
Right-of-use assets (USD) — — — 195M 175M 178M 150M 154M 177M 183M
Net debt (borrowings + leases - cash) (USD) -377M -667M -448M 1.03B 918M 1.43B -865M -1.43B -1.1B -1.3B
Cash flow detail
Operating cash flow (USD) 793M 889M 1.09B 1.02B 921M 1.49B 1.31B 1.77B 1.75B 1.56B
Purchases of property, plant and equipment (USD) -139M -176M -177M -155M -119M -188M -291M -298M -378M -407M
Purchases of intangible assets (USD) — 0.00 0.00 -1M 0.00 -1M — — — —
Change in receivables (cash effect) (USD) -33M -81M -65M -106M -107M -128M -321M 132M 7M -149M
Change in inventories (cash effect) (USD) -7M -61M -83M -36M -68M -136M -248M -33M 34M -97M
Change in payables (cash effect) (USD) -15M 2M 40M 29M 2M 64M 121M -171M 103M 16M
Dividends paid (cash effect) (USD) -150M -170M -191M -206M -222M -236M -250M -265M -274M -282M
Share buybacks (cash effect) (USD) -434M -194M -422M -723M -469M -788M -1.14B -575M -1.15B -425M
Interest paid (cash effect) (USD) -73M -82M -80M -80M -71M -76M -85M -89M -80M -101M
Income taxes paid (cash effect) (USD) -67M -63M -102M -159M -361M -211M -279M -199M -314M -318M
Share-based compensation (USD) 58M 60M 70M 72M 83M 110M 125M 111M 129M 128M
Operating cash flow before change in receivables (USD) 826M 970M 1.15B 1.13B 1.03B 1.61B 1.63B 1.64B 1.74B 1.71B
Free cash flow (OCF - PPE - intangibles) (USD) 654M 713M 910M 865M 802M 1.3B 1.02B 1.47B 1.37B 1.15B
Income detail
Research and development expense (USD) 329M 339M 385M 404M 495M 441M 467M 481M 479M 455M
↳ 5y CAGR -12.7% -12.7% -11.4% -10.9% +8.4% +6.0% +6.6% +4.6% +3.5% -1.7%
Total comprehensive income (USD) 350M 841M 254M 972M 711M 1.45B 1.19B 1.26B 1.31B 1.38B
Comprehensive income to owners (USD) 350M 841M 254M 972M 711M 1.45B 1.19B 1.26B 1.31B 1.38B
Reported Mar 8, 2017 Dec 19, 2019 Dec 19, 2019 Dec 19, 2019 Dec 17, 2021 Dec 17, 2021 Dec 21, 2022 Dec 20, 2023 Dec 20, 2024 Dec 22, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Agilent Completes Acquisition of Proscia Bull 2 Bear 0 M&A

November 4, 2026

Expands Agilent’s pathology portfolio and establishes a platform for scientific intelligence in tissue-based precision medicine

Strengthens Agilent’s ability to support customers across clinical diagnostics, biopharma and life-sciences research

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Proscia®, a leading provider of digital-pathology software for clinical and life-sciences customers. Under the terms of the transaction, Agilent acquired Proscia for $240 million in cash at closing, with up to an additional $30 million payable based on the achievement of future performance milestones. Following the closing of the transaction, Proscia is now part of Agilent's Life Sciences and Diagnostics Markets Group.

“We’re pleased to complete our acquisition of Proscia, further strengthening Agilent’s pathology portfolio and establishing a platform for scientific intelligence,” said Agilent President and CEO Padraig McDonnell. “Proscia’s talented team and leading vendor-agnostic digital-pathology platform enhance our ability to support customers across clinical diagnostics, biopharma, and life-sciences research. Together, Agilent and Proscia are well positioned to advance AI-enabled pathology workflows, accelerate drug discovery and companion-diagnostics solutions, and create long-term value for customers and shareholders.”

The completed transaction combines Agilent's pathology instrumentation and reagents with Proscia's vendor-agnostic digital-pathology platform which comes with FDA 510(k) clearance for primary diagnosis and an established customer base. Proscia’s platform adds a recurring-revenue software business to Agilent’s pathology portfolio and expands the company’s ability to support companion-diagnostics development, biopharma drug discovery, and clinical-pathology workflows through AI-enabled tools and a growing repository of real-world data.

Advisers

DLA Piper LLP (US) served as legal adviser and Joele Frank served as strategic communications adviser to Agilent.

Cooley LLP served as legal adviser to Proscia.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com . To receive the latest Agilent news, subscribe to the Agilent Newsroom . Follow Agilent on LinkedIn and Facebook .

About Proscia

Proscia is the pathology AI company rewiring pathology for precision medicine across drug discovery, development, and diagnosis. Its Concentriq platform brings intelligence to the scientists, pathologists, and laboratory leaders behind the most critical decisions in medicine, helping more breakthroughs reach the patients they were made for. Proscia is trusted by 16 of the top 20 pharmaceutical companies and was named Global 2026 Best in KLAS for Digital Pathology in Europe. Learn more at proscia.com , and follow Proscia on LinkedIn and X .

Forward-Looking Statements

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of applicable U.S. securities laws. All statements herein other than historical facts, including, without limitation, statements regarding Agilent management’s current expectations, assumptions, estimates and projections regarding the industry in which Agilent operates, general economic conditions, Agilent’s businesses and its financial performance or condition, and future events, including the acquisition of Proscia and its anticipated benefits referred to in this press release, are forward-looking statements. Such forward-looking statements rely on the safe harbor provisions of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Because such forward-looking statements are subject to risks and uncertainties, actual results and future trends may differ materially from those expressed in or implied by such forward-looking statements. Accordingly, potential investors and Agilent securityholders should not place undue reliance on such forward-looking statements. Words and phrases such as “anticipate,” “believe,” “combined company,” “could,” “consider,” “create,” “drive,” “expect,” “forecast,” “future,” “growth,” “hope,” “intend,” “opportunity,” “plan,” “potential,” “projected,” “proposal,” “result in,” “synergies,” “unlock,” “upside,” “will,” “would,” and similar words and phrases are intended to identify forward-looking statements. Among the risks and uncertainties that could cause actual results to differ from those described in forward-looking statements are the following: risks relating to the future performance, results of operations, liquidity and financial position of each of Agilent, Proscia and the combined company resulting from the consummation of the transaction with Proscia; the possibility that the combined company following consummation of the transaction with Proscia may not achieve expected synergies and operating efficiencies within the expected timeframes, or at all; the risk that consummating the transaction with Proscia may be less accretive than expected, or may be dilutive, to Agilent’s earnings per share, which may negatively affect the market price of Agilent’s common stock; the risk that the integration of Proscia’s operations with those of Agilent may be more difficult, time-consuming and costly than expected, or that operating costs and business disruption may be greater than expected; the risk that the completion of the transaction with Proscia could have an adverse effect on the market price of Agilent’s common stock; the risk that Agilent and Proscia may incur significant transaction and other costs in connection with the transaction, and that those costs may exceed those anticipated by Agilent; and risks related to any unforeseen liabilities of, and future capital expenditures required by, Agilent following consummation of the transaction with Proscia.

Additional risks and uncertainties relating to forward-looking statements in respect of Agilent’s businesses, operations, prospects and financial performance and condition can be found in Agilent’s filings with the Securities and Exchange Commission (the “SEC”), including the risks, uncertainties and other factors discussed in the sections entitled “Risk Factors” and “Forward-Looking Statements” in Agilent’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025, filed with the SEC on December 19, 2025, and the other filings Agilent has made or will make with the SEC after such date, copies of which may be obtained from the SEC’s website at www.sec.gov . All forward-looking statements contained herein are made only as of the date hereof, and Agilent disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which Agilent hereafter becomes aware, except as required by applicable law.

INVESTOR CONTACT
Tejas Savant
+1 917-574-4018
[email protected]

MEDIA CONTACT
Christian Colón
+1 302-867-4117
[email protected]

Source: Agilent Technologies Inc.

Multimedia Files:

Visit Newsroom

Investor Contact


Agilent Technologies

Investor Relations

5301 Stevens Creek Blvd. MS 1A-IR

Santa Clara, CA 95051

E-mail Us

Are you a Shareholder with a Question?

Computershare is Agilent's Transfer Agent and can help with questions about your stock, including address changes, dividends, lost stock certificates, estates/deceased shareholders.

Within the U.S. or Canada: 877-309-9856

Non-US: 312-588-4991

E-mail: [email protected]

Mailing List

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Agilent, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Agilent to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

Press Releases
Events
Presentations
SEC Filings
End of Day Stock Quote
Annual Reports
Captcha
Enter the code shown above.
*

Submit

Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

© 2026 Agilent Technologies, Inc.

November 2, 2026

Single quadrupole mass selective detector delivers up to 25% faster scan speed, an order-of-magnitude improvement in dynamic range and up to 40% lower energy consumption

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced the launch of the 5987A single quadrupole mass selective detector (MSD) with GC Assist, along with MassHunter 14 software. When combined with the Agilent 8890B or 8860B gas chromatograph, the 5987A creates an integrated GC/MS system designed to help laboratories improve data quality, reduce unplanned downtime and operate more efficiently.

The 5987A delivers up to a 25% increase in scan rate while maintaining data quality, enabling two new modes of operation supported by MassHunter 14 software. Dynamic SIM, or dSIM, maximizes dwell time to improve sensitivity and peak shape, while simultaneous dSIM/Scan captures low-level SIM data and library-searchable full-scan results in a single analysis. Optimizer, a method development capability in MassHunter 14, automates the creation, updating and maintenance of SIM methods, making growing compound databases easier for laboratories to manage.

“Laboratories need analytical systems that help them generate high-quality data while managing growing workloads and limited resources,” said Warren Potts, vice president and general manager of the Gas Phase Division at Agilent. “The 5987A combines advanced analytical performance with built-in system intelligence, helping scientists identify potential issues earlier, simplify routine maintenance and remain focused on their analytical work.”

GC Assist provides integrated system monitoring, troubleshooting and maintenance guidance across the GC/MS workflow. It can monitor and record more than 60 system parameters, notify scientists when maintenance is required, flag results that fall outside predefined quality control limits, and provide step-by-step maintenance procedures and onboard videos. Scientists can also monitor instrument status and troubleshoot systems remotely within the laboratory’s secure network.

Across the integrated system, GC Assist can monitor system performance, gas and power usage, and indicators of carrier gas leaks. By helping laboratories identify potential issues before they affect results, the system can reduce reruns associated with system issues or unmet quality control criteria, saving time and resources. The 5987A also reduces energy consumption by up to 40% compared with previous Agilent GC/MSD systems, helping laboratories support their operational sustainability goals.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com . To receive the latest Agilent news, subscribe to the Agilent Newsroom . Follow Agilent on LinkedIn and Facebook .

MEDIA CONTACT:
Christian Colón
+1 302-867-4117
[email protected]

Source: Agilent Technologies Inc.

Multimedia Files:

Visit Newsroom

Investor Contact


Agilent Technologies

Investor Relations

5301 Stevens Creek Blvd. MS 1A-IR

Santa Clara, CA 95051

E-mail Us

Are you a Shareholder with a Question?

Computershare is Agilent's Transfer Agent and can help with questions about your stock, including address changes, dividends, lost stock certificates, estates/deceased shareholders.

Within the U.S. or Canada: 877-309-9856

Non-US: 312-588-4991

E-mail: [email protected]

Mailing List

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Agilent, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Agilent to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

Press Releases
Events
Presentations
SEC Filings
End of Day Stock Quote
Annual Reports
Captcha
Enter the code shown above.
*

Submit

Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

© 2026 Agilent Technologies, Inc.

October 29, 2026

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) will release financial results for the fourth quarter of fiscal year 2026 after the stock market closes on Monday, Nov. 23. The company will host a conference call to discuss the results at 1:30 p.m. PST the same day.

To join the listen-only conference-call webcast, click the link on the Events section of Agilent’s Investor Relations website. A recording of the call will also be available on the website for 90 days.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com . To receive the latest Agilent news, subscribe to the Agilent Newsroom . Follow Agilent on LinkedIn and Facebook .

INVESTOR CONTACT:
Tejas Savant
+1 917-574-4018
[email protected]

MEDIA CONTACT:
Christian Colón
+1 302 867 4117
[email protected]

Source: Agilent Technologies Inc.

Multimedia Files:

Visit Newsroom

Investor Contact


Agilent Technologies

Investor Relations

5301 Stevens Creek Blvd. MS 1A-IR

Santa Clara, CA 95051

E-mail Us

Are you a Shareholder with a Question?

Computershare is Agilent's Transfer Agent and can help with questions about your stock, including address changes, dividends, lost stock certificates, estates/deceased shareholders.

Within the U.S. or Canada: 877-309-9856

Non-US: 312-588-4991

E-mail: [email protected]

Mailing List

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Agilent, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Agilent to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

Press Releases
Events
Presentations
SEC Filings
End of Day Stock Quote
Annual Reports
Captcha
Enter the code shown above.
*

Submit

Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

© 2026 Agilent Technologies, Inc.

Prompts

Agilent Technologies, Inc. (ticker A), listed in United States.

Company History

Date Change Detail
May 15, 2007 Acquired Acquired Stratagene Corp (CIK 1108674). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Agilent Technologies, Inc.

ETF Weight in ETF Shares Market value As of
BEEZ 4.90% 1,737 $ 300K Nov 18, 2026
GKAT 4.19% 50,461 $ 6.703M Jun 30, 2026
CVRD 3.95% 9,500 $ 1.262M Jun 30, 2026
GDOC 3.51% 4,485 $ 688.717K Aug 31, 2026
KAT 3.51% 172,044 $ 22.853M Jun 30, 2026
TMED 2.61% 4,530 $ 601.72K Jun 30, 2026
BMED 2.38% 1,973 $ 341.171K Nov 16, 2026
EPMB 1.90% 509 $ 88.546K Nov 13, 2026
MMID 1.49% 3,506 $ 538.381K Aug 31, 2026
PSET 1.29% 2,797 $ 371.526K Jun 30, 2026
BKDV 1.05% 139,923 $ 19.361M Jul 31, 2026
CVAR 0.88% 2,720 $ 376.366K Jul 31, 2026
FWD 0.75% 155,415 $ 23.866M Aug 31, 2026
AIVL 0.73% 22,923 $ 3.045M Jun 30, 2026
LCLG 0.65% 5,068 $ 701.259K Jul 31, 2026
WINN 0.60% 43,591 $ 7.583M Nov 13, 2026
HELX 0.58% 1,223 $ 162.451K Jun 30, 2026
TMAT 0.55% 9,383 $ 1.298M Jul 31, 2026
AVMC 0.54% 17,356 $ 3.001M Nov 16, 2026
BAMV 0.51% 3,857 $ 592.281K Aug 31, 2026
DFLV 0.37% 164,747 $ 28.503M Nov 12, 2026
ACLC 0.37% 7,825 $ 1.202M Aug 31, 2026
CDX 0.25% 3,546.3009 $ 610.744K Nov 17, 2026
LCTU 0.23% 15,065 $ 2.605M Nov 16, 2026
FLSP 0.21% 14,763 $ 1.961M Jun 30, 2026
DFUV 0.18% 163,945 $ 28.364M Nov 12, 2026
CAPE 0.17% 3,098 $ 411.507K Jun 30, 2026
DFVX 0.17% 5,620 $ 972.316K Nov 12, 2026
HBTA 0.13% 2,027 $ 311.266K Aug 31, 2026
LGDX 0.12% 968 $ 167.387K Nov 17, 2026
XMAG 0.11% 1,384 $ 239.446K Nov 13, 2026
MODL 0.11% 8,475 $ 1.126M Jun 30, 2026
DFSU 0.10% 13,169 $ 2.278M Nov 12, 2026
MPLY 0.09% 108 $ 14.944K Jul 31, 2026
VSLU 0.09% 3,551 $ 471.679K Jun 30, 2026
DFAU 0.08% 63,431 $ 10.974M Nov 12, 2026
INRO 0.08% 2,563 $ 443.194K Nov 16, 2026
AAUS 0.08% 2,260 $ 390K Nov 18, 2026
APUE 0.07% 12,151 $ 1.866M Aug 31, 2026
TACU 0.07% 76 $ 13.142K Nov 17, 2026
DFUS 0.07% 89,526 $ 15.489M Nov 12, 2026
DXUV 0.07% 25,695 $ 4.445M Nov 12, 2026
AVLC 0.07% 6,061 $ 1.048M Nov 16, 2026
DFAC 0.07% 339,751 $ 58.78M Nov 12, 2026
AVSU 0.06% 1,708 $ 295.347K Nov 16, 2026
DCOR 0.06% 156,166 $ 27.018M Nov 12, 2026
VOXP 0.06% 24 $ 3,320.88 Jul 31, 2026
NTSD 0.06% 150 $ 19.925K Jun 30, 2026
NTSX 0.06% 5,732 $ 761.382K Jun 30, 2026
GDE 0.05% 1,721 $ 264.277K Aug 31, 2026
ACVF 0.05% 568 $ 78.594K Jul 31, 2026
HCMT 0.05% 1,965 $ 271.897K Jul 31, 2026
MSLC 0.04% 10,996 $ 1.689M Aug 31, 2026
AVUS 0.04% 33,550 $ 5.801M Nov 16, 2026
IALT 0.03% 15,980 $ 2.763M Nov 16, 2026
CSHP 0.02% 505 $ 87.325K Nov 16, 2026
GSPY 0.02% 997 $ 172.401K Nov 17, 2026
EBI 0.01% 595 $ 91.368K Aug 31, 2026
ACGR 0.00% 294 $ 45.147K Aug 31, 2026
CORO 0.00% 178 $ 30.803K Nov 16, 2026